First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases
作者:Ulrike E. Hille、Christina Zimmer、Carsten A. Vock、Rolf W. Hartmann
DOI:10.1021/ml100071j
日期:2011.1.13
concept, we succeeded in the development of a series of highly active and selective inhibitors of CYP11B1, the key enzyme of cortisol biosynthesis, as potential drugs for the treatment of Cushing's syndrome and related diseases. Thus, compound 33 (IC50 = 152 nM) is the first CYP11B1 inhibitor showing a rather good selectivity toward the most important steroidogenic CYP enzymes aldosterone synthase (CYP11B2)
从基于依托咪酯的设计概念出发,我们成功开发了一系列高活性和选择性抑制剂CYP11B1(皮质醇生物合成的关键酶),作为治疗库欣综合症和相关疾病的潜在药物。因此,化合物33(IC50 = 152 nM)是第一种CYP11B1抑制剂,对最重要的类固醇生成CYP酶醛固酮合酶(CYP11B2),形成雄激素的CYP17和芳香酶(雌激素合酶CYP19)表现出相当好的选择性。